Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

Archives of Internal Medicine

Volumn 156, Issue 18, 1996, Pages 2085-2092

  Pedersen, Terje R ^a,j   Berg, Káre ^a   Cook, Thomas J ^b   Færgeman, Ole ^c   Haghfelt, Torben ^d   Kjekshus, John ^a   Miettinen, Tatu ^e   Musliner, Thomas A ^b   Olsson, Anders G ^f   Pyörälä, Kalevi ^g   Thorgeirsson, Gudmundur ^h   Tobert, Jonathan A ^b   Wedel, Hans ⁱ   Wilhelmsen, Lars ⁱ  

^a UNIVERSITY OF OSLO   (Norway)

^b MERCK RESEARCH LABORATORIES   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF HELSINKI   (Finland)

^f LINKÖPING UNIVERSITY   (Sweden)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h REYKJAVIK UNIVERSITY   (Iceland)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j AKER UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; SIMVASTATIN;

ANGINA PECTORIS; ARTICLE; CATARACT; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MYOPATHY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCANDINAVIA; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; DOUBLE-BLIND METHOD; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MIDDLE AGED; SIMVASTATIN;

EID: 10244249180     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.18.2085     Document Type: Article

References (27)

1. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50:334-363.
2. MAAS Investigators. Effect of Simvastatin on coronary atheroma: the Multi-centre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from 4S. Am J Cardiol. 1995;76:64C-68C.
5. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
6. Oliver M, Poole-Wilson P, Shepherd J, Tikkanen M. Lower patients' cholesterol now. BMJ. 1995;310:1280-1281.
7. Wood DA. Cholesterol lowering does have a role in secondary prevention. Br Heart J. 1995;73:4-5.
8. Kennedy JW. President's page: expanding the role of the American College of Cardiology. J Am Coll Cardiol. 1995;26:289-290.
9. Smith SC, Blair SN, Criqui MH, et al. AHA consensus panel statement: preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
10. Oliver MF. Doubts about preventing coronary heart disease: multiple interventions in middle-aged men may do more harm than good. BMJ. 1992;304:393-394.
11. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992;304:431-434.
12. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-314.
13. Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol: time to change directions. Circulation. 1992;86:1026-1029.
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
15. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990;50:65-78.
16. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282
17. Gordon D. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Lowering Cholesterol in High-Risk Individuals and Populations. New York, NY: Marcel Dekker Inc; 1995:33-47.
18. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. Arch Intern Med. 1991;151:43-49.
19. Tobert JA. Efficacy and long term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.
20. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994;15:255-269.
21. Scott WA. Hydrophilicity and the differential pharmacology of pravastatin. In: Wood C, ed. Lipid Management: Pravastatin and the Differential Pharmacology of HMG-CoA Reductase Inhibitors. London, England: Royal Society of Medicine Services; 1989;16:17-25. Round Table Series.
22. Schaefer EJ. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988;319:122.
23. Keech AC, Armitage JM, Wallendszus KR, Lawson A, Hauer AJ, Parish SE, Collins R, for the Oxford Cholesterol Study Group. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomised placebocontrolled study. Br J Clin Pharmacol. In press.
24. Eckemas SA, Roos BE, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993;35:284-289.
25. Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? a comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37:231-236.
26. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
27. Harris ML, Bron AJ, Brown NAP, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo-controlled study. Br J Ophthalmol. 1995;79:996-1002.